{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:13:37Z","timestamp":1767852817304,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.vaccine.2017.05.043","type":"journal-article","created":{"date-parts":[[2017,6,3]],"date-time":"2017-06-03T03:16:10Z","timestamp":1496459770000},"page":"3764-3772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib)"],"prefix":"10.1016","volume":"35","author":[{"given":"Federico","family":"Martin\u00f3n-Torres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Boisnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Sadorge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.05.043_b0005","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1515\/REVEH.2005.20.4.303","article-title":"Environmentally and occupationally acquired diseases in adolescents and adulthood: control of diphtheria, tetanus, pertussis, and poliomyelitis through regular booster vaccinations \u2013 a European perspective","volume":"20","author":"Hofmann","year":"2005","journal-title":"Rev Environ Health"},{"key":"10.1016\/j.vaccine.2017.05.043_b0010","unstructured":"European Centre for Disease Prevention and Control (ECDC) Vaccine Schedule. Available at: http:\/\/vaccine-schedule.ecdc.europa.eu [accessed 26 September 2016]."},{"key":"10.1016\/j.vaccine.2017.05.043_b0015","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/INF.0b013e31805d7f17","article-title":"Use of combination vaccines is associated with improved coverage rates","volume":"26","author":"Marshall","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.05.043_b0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/01.inf.0000222413.47344.23","article-title":"The use of combination vaccines has improved timeliness of vaccination in children","volume":"25","author":"Kalies","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.05.043_b0025","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1080\/21645515.2015.1044180","article-title":"The value of childhood combination vaccines: from beliefs to evidence","volume":"11","author":"Maman","year":"2015","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.vaccine.2017.05.043_b0030","first-page":"e1","article-title":"Immunization schedule of the Spanish Association of Pediatrics: 2012 recommendations","author":"Moreno-P\u00e9rez","year":"2012","journal-title":"An Pediatr (Barc)"},{"key":"10.1016\/j.vaccine.2017.05.043_b0035","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assay. The Multilaboratory Study group","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2017.05.043_b0040","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1128\/CVI.00260-12","article-title":"Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine","volume":"19","author":"Khalil","year":"2012","journal-title":"Clin Vacc Immunol"},{"key":"10.1016\/j.vaccine.2017.05.043_b0045","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1128\/JCM.26.1.72-78.1988","article-title":"Variable quantitation of Haemophilus influenzae type b anticapsular antibody by radioantigen binding assay","volume":"26","author":"Ward","year":"1988","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2017.05.043_b0050","series-title":"Modelling binary data","author":"Collett","year":"2002"},{"key":"10.1016\/j.vaccine.2017.05.043_b0055","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1542\/peds.2014-4102","article-title":"Immunogenicity, safety, and tolerability of a hexavalent vaccine in infants","volume":"136","author":"Marshall","year":"2015","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.vaccine.2017.05.043_b0060","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/INF.0000000000001405","article-title":"Lot-to-lot consistency, safety, tolerability, and immunogenicity of an investigational hexavalent vaccine in US infants","volume":"36","author":"Block","year":"2017","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.vaccine.2017.05.043_b0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/INF.0000000000001406","article-title":"A phase III, randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 3, 4, and 12 Months","author":"Vesikari","year":"2017","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.vaccine.2017.05.043_b0070","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1016\/j.vaccine.2016.05.054","article-title":"A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11\u201312 months","volume":"34","author":"Silfverdal","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.043_b0075","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/147.6.1100","article-title":"The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b","volume":"147","author":"K\u00e4yhty","year":"1983","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.043_b0080","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/hep.1840010502","article-title":"A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report","volume":"1","author":"Szmuness","year":"1981","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2017.05.043_b0085","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/bmj.286.6374.1305","article-title":"Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial","volume":"286","author":"Coutinho","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"9 Suppl","key":"10.1016\/j.vaccine.2017.05.043_b0090","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1097\/00006454-199809001-00004","article-title":"Haemophilus influenzae type b vaccines: history, choice and comparisons","volume":"17","author":"Decker","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.05.043_b0095","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/INF.0b013e3182717edf","article-title":"Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without heptavalent pneumococcal conjugate vaccine: a randomized, open-label study","volume":"32","author":"Tapi\u00e9ro","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.05.043_b0100","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.vaccine.2010.11.053","article-title":"Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12\u201314 months of age","volume":"29","author":"Diaz-Mitoma","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.043_b0105","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1016\/j.vaccine.2008.11.115","article-title":"Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12\u201314 months of age","volume":"27","author":"Halperin","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.043_b0110","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4161\/hv.1.6.2377","article-title":"Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children","volume":"1","author":"Halperin","year":"2005","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2017.05.043_b0115","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1128\/CVI.00420-08","article-title":"Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom","volume":"16","author":"Southern","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.05.043_b0120","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1016\/j.vaccine.2013.04.070","article-title":"Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C\u00ae) in infants","volume":"31","author":"Poellabauer","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.043_b0125","unstructured":"Vesikari T, Boisnard F, Richard P, Lockhart S. Concomitant administration of a fully liquid, ready-to-use hexavalent vaccine DTaP-IPV-HB-Hib with a meningococcal serogroup C vaccine in infants [abstract]. In: Abstracts of the 33rd annual meeting of the European society for paediatric infectious diseases (ESPID); 2015 May 12\u201316; Liepzig, Germany. Abstract no. 0330. Available at: http:\/\/espid2015.kenes.com\/Documents\/ESPID%202015%20Abstracts.pdf [accessed on 26 September 2016]."},{"key":"10.1016\/j.vaccine.2017.05.043_b0130","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/INF.0b013e31824b972b","article-title":"13-Valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety","volume":"31","author":"Martin\u00f3n-Torres","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.05.043_b0135","unstructured":"Oliver JL, Snape MD, Heath PT, Faust SN, Tomlinson R, Rudd P et al. Investigational hexavalent vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during primary series infants [abstract]. In: Abstracts of the 33rd annual meeting of the european society for paediatric infectious diseases (ESPID); 2015 May 12\u201316; Liepzig, Germany. Abstract no. 0936. Available at: http:\/\/espid2015.kenes.com\/Documents\/ESPID%202015%20Abstracts.pdf [accessed on 26 September 2016]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17306795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17306795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T10:55:43Z","timestamp":1602240943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17306795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":27,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0264410X17306795"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}